Hidoc Dr | Medical Learning App for Doctors

Today's Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

Published Date: 16 Sep 2026

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

Published Date: 16 Sep 2026

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

Published Date: 16 Sep 2026

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Published Date: 16 Sep 2026

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Knowledge Hub

Oncology

Tumor-Derived Exosomal Proteins and Cancer Progression

Comprehensive review of tumor-derived exosomal proteins and their impact on cancer progression for clinical practice.

Oncology

Screening for Cancer-Treatment-Related Bone Loss: Clinical Implications and Evidence-Based Strategies

Comprehensive review of screening and management strategies for cancer-treatment-related bone loss.

Oncology

Targeted Degradation in Breast Cancer: Mechanisms, Clinical Applications, and Future Perspectives

Comprehensive review of targeted protein degradation strategies in breast cancer, mechanisms, clinical impact, and future advances.

Oncology

Oncology Drug Handling Near-Misses: Clinical Risks, Pathophysiology, and Guideline-Based Approaches

Comprehensive review of near-misses in oncology drug handling, covering risks, mechanisms, prevention, and guidelines for healthcare professionals.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

Could Burnout Become the Employer’s Responsibility?

High CLL Remission Seen With First-Line Triplet Regimen

FET-PET Agent Approved for Glioma Imaging

Knowledge Hub

Tumor-Derived Exosomal Proteins and Cancer Progression

Screening for Cancer-Treatment-Related Bone Loss: Clinical Implications and Evidence-Based Strategies

Targeted Degradation in Breast Cancer: Mechanisms, Clinical Applications, and Future Perspectives

Oncology Drug Handling Near-Misses: Clinical Risks, Pathophysiology, and Guideline-Based Approaches

Molecular Glues for Solid Tumors: Mechanistic Insights, Clinical Relevance, and Therapeutic Potential

Therapeutic RNA Vaccines for Cancer: Mechanisms, Clinical Applications, and Future Directions

Exercise Capacity During Cancer Recovery: Clinical Evidence, Mechanisms, and Practical Implications

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

Could Burnout Become the Employer’s Responsibility?

High CLL Remission Seen With First-Line Triplet Regimen

FET-PET Agent Approved for Glioma Imaging

Knowledge Hub

Tumor-Derived Exosomal Proteins and Cancer Progression

Screening for Cancer-Treatment-Related Bone Loss: Clinical Implications and Evidence-Based Strategies

Targeted Degradation in Breast Cancer: Mechanisms, Clinical Applications, and Future Perspectives

Oncology Drug Handling Near-Misses: Clinical Risks, Pathophysiology, and Guideline-Based Approaches

Molecular Glues for Solid Tumors: Mechanistic Insights, Clinical Relevance, and Therapeutic Potential

Therapeutic RNA Vaccines for Cancer: Mechanisms, Clinical Applications, and Future Directions

Exercise Capacity During Cancer Recovery: Clinical Evidence, Mechanisms, and Practical Implications

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views